Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a leading biopharmaceutical company based in China, has announced the upcoming retirement of Harald Reinhart, M.D., who serves as the President and Head of Global Development for Neuroscience, Autoimmune, and Infectious Diseases (NSAiID). Dr. Reinhart’s tenure will conclude on June 30th, 2024. In conjunction with this change, Rafael Amado, M.D., currently the President and Head of Global Oncology Research and Development at Zai Lab, will expand his remit to include oversight of the company’s entire Global R&D portfolio following Dr. Reinhart’s departure.
As the new Head of Global R&D, Dr. Amado is poised to further strengthen Zai Lab’s pipeline, both existing and forthcoming, across all therapeutic areas. With an extensive background that includes senior roles and advisory positions in numerous pharmaceutical and biotechnology firms, Dr. Amado brings a wealth of experience in product discovery and development, spanning diverse modalities and therapeutic areas.- Flcube.com
